Free Trial

Windle Wealth LLC Raises Position in Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logo with Medical background

Windle Wealth LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 48,524 shares of the company's stock after purchasing an additional 2,868 shares during the quarter. Johnson & Johnson comprises about 4.1% of Windle Wealth LLC's holdings, making the stock its 13th biggest holding. Windle Wealth LLC's holdings in Johnson & Johnson were worth $8,047,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. increased its position in Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after acquiring an additional 1,772,706 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Johnson & Johnson by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock valued at $8,321,881,000 after purchasing an additional 1,561,036 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after buying an additional 3,363,235 shares during the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $4,390,037,000. Finally, Wellington Management Group LLP grew its position in Johnson & Johnson by 1.8% during the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock valued at $3,522,447,000 after buying an additional 431,205 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.4%

NYSE:JNJ traded up $0.68 during midday trading on Monday, hitting $164.38. 8,202,992 shares of the company traded hands, compared to its average volume of 8,141,586. The firm has a market capitalization of $395.51 billion, a P/E ratio of 16.37, a P/E/G ratio of 2.08 and a beta of 0.41. The firm's fifty day moving average is $154.29 and its 200-day moving average is $155.12. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the company posted $2.82 EPS. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.16%. Johnson & Johnson's payout ratio is currently 55.61%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Barclays lifted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday. Bank of America boosted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday. UBS Group reaffirmed a "buy" rating and issued a $190.00 price objective (up previously from $180.00) on shares of Johnson & Johnson in a research note on Thursday. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Raymond James Financial lowered their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Eleven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $172.87.

Read Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines